Cat. No.: HY-N0102

Isoliquiritigenin

(Synonyms: GU17; ISL; Isoliquiritigen; SJ000286237)

32 Cited Publications

Customer Review

Based on 32 publication(s) in Google Scholar

Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza uralensis Fisch., which inhibits aldose reductase with an IC₅₀ of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC₅₀ of 24.7 μM.

For research use only. We do not sell to patients.

Purity: 99.87%
CAS No.: 961-29-5
Formula: C₁₅H₁₂O₄
Molecular Weight:256.25

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Isoliquiritigenin Chemical Structure

CAS No.: 961-29-5

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (32)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 320 nM (Aldose reductase)

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	96.4 μM Compound: 10	Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining	[PMID: 19757853]
A549	IC₅₀	98.9 μM Compound: 28	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18440233]
A549	IC₅₀	>20 μM Compound: 3	Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay	[PMID: 19883086]
A549	IC₅₀	85 μM Compound: 20	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
A549	GI₅₀	87 μM Compound: 11	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
A549	IC₅₀	52.58 μM Compound: ISL	Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
B16-BL6	IC₅₀	80.5 μM Compound: 28	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 18440233]
BV-2	IC₅₀	>100 μM Compound: 8	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
BV-2	IC₅₀	5.22 μM Compound: 137; 154	Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production pre-treated with compounds for 2 hrs followed by LPS-stimulation measured for 22 hrs by Griess reagent based analysis Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production pre-treated with compounds for 2 hrs followed by LPS-stimulation measured for 22 hrs by Griess reagent based analysis	[PMID: 37683361]
BV-2	IC₅₀	6.78 μM Compound: 137; 154	Antiinflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production incubated for 24 hrs by microplate reader analysis Antiinflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production incubated for 24 hrs by microplate reader analysis	[PMID: 37683361]
C2C12	IC₅₀	26.34 μg/mL Compound: 11	Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay	[PMID: 33412152]
C-33-A	IC₅₀	32.83 μM Compound: 2	Cytotoxicity against human C33A cells assessed as reduction in cell viability after 72 hrs Cytotoxicity against human C33A cells assessed as reduction in cell viability after 72 hrs	[PMID: 31539776]
Ca-Ski	IC₅₀	39.09 μM Compound: 2	Cytotoxicity against human CaSki cells assessed as reduction in cell viability after 72 hrs Cytotoxicity against human CaSki cells assessed as reduction in cell viability after 72 hrs	[PMID: 31539776]
CHO	IC₅₀	45.9 μM Compound: 13	Cytotoxicity against CHO cells by MTT assay Cytotoxicity against CHO cells by MTT assay	[PMID: 19572738]
HCT-116	GI₅₀	39 μM Compound: 11	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 32345458]
HEK-293T	IC₅₀	3.42 μg/mL Compound: 6	Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	[PMID: 21123068]
HEK-293T	IC₅₀	3.48 μg/mL Compound: 6	Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry	[PMID: 21123068]
HeLa	IC₅₀	82.6 μM Compound: 28	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18440233]
HeLa	IC₅₀	58.1 μM Compound: 2	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs	[PMID: 31539776]
HeLa	IC₅₀	58.1 μM Compound: 2	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31539776]
HepG2	IC₅₀	27.71 μM Compound: ISL	Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
HT-1080	IC₅₀	76.7 μM Compound: 28	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 18440233]
Huh-7	CC₅₀	>50 μM Compound: 24	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	36.1 μM Compound: 24	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
HUVEC	IC₅₀	41.17 μM Compound: Isoliquiritigein	Toxicity against HUVEC incubated for 48 hrs by MTT assay Toxicity against HUVEC incubated for 48 hrs by MTT assay	[PMID: 25590864]
J774.1	IC₅₀	29.3 μM Compound: 16	Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay	[PMID: 15974608]
K562	IC₅₀	32 μM Compound: Isoliquiritigenin	Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay	[PMID: 24775915]
K562	IC₅₀	29.27 μM Compound: Isoliquiritigein	Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay	[PMID: 25590864]
KB	CC₅₀	12 μM Compound: 10c	Compound concentration required to reduce the exponential growth of KB cells by 50% Compound concentration required to reduce the exponential growth of KB cells by 50%	[PMID: 9767632]
L02	IC₅₀	>1000 μM Compound: 2	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31539776]
Lewis lung carcinoma cell line	IC₅₀	84 μM Compound: 28	Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay	[PMID: 18440233]
LoVo	IC₅₀	57 μM Compound: 20	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
MCF-10A	IC₅₀	25 μM Compound: Isoliquiritin	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay	[PMID: 33257172]
MCF7	IC₅₀	>10 μM Compound: Isoliquiritigenin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26690274]
MCF7	GI₅₀	>100 μM Compound: 11	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32345458]
MCF7	IC₅₀	17.67 μM Compound: ISL	Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
MDA-MB-231	IC₅₀	>10 μM Compound: Isoliquiritigenin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26690274]
MDA-MB-231	IC₅₀	25 μM Compound: Isoliquiritin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 to 96 hrs by MTT assay	[PMID: 33257172]
MDA-MB-231	IC₅₀	10.86 μM Compound: ISL	Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 34186178]
MT4	CC₅₀	7.4 μM Compound: 10c	Compound concentration required to reduce the exponential growth of MT-4 cells by 50% Compound concentration required to reduce the exponential growth of MT-4 cells by 50%	[PMID: 9767632]
NIH3T3	IC₅₀	4.8 μM Compound: 1c	Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay	[PMID: 21112783]
PANC-1	IC₅₀	3.3 μM Compound: 9	Cytotoxicity against human PANC1 cells after 72 hrs by WST8 assay Cytotoxicity against human PANC1 cells after 72 hrs by WST8 assay	[PMID: 28495081]
PC-12	IC₅₀	17.8 μM Compound: 2	Cytotoxicity against rat PC12 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against rat PC12 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31539776]
PC-3	IC₅₀	46.4 μM Compound: 9	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 16441066]
PC-3	IC₅₀	99 μM Compound: 20	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
RAW264.7	IC₅₀	72 μM Compound: 12	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 23743282]
RAW264.7	IC₅₀	3.4 μg/mL Compound: 202	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent based assay	[PMID: 31255927]
RBL-1	IC₅₀	35 μM Compound: 6	In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined	[PMID: 8254620]
RBL-1	IC₅₀	35 μM Compound: 5	Inhibition of 5-lipoxygenase in rat RBL1 cells Inhibition of 5-lipoxygenase in rat RBL1 cells	10.1007/s00044-013-0745-7
RBL-1	IC₅₀	35 μM Compound: 5	Inhibition of cyclooxygenase in rat RBL1 cells Inhibition of cyclooxygenase in rat RBL1 cells	10.1007/s00044-013-0745-7
RBL-2H3	IC₅₀	>30 μM Compound: Isoliquiritigenin	Antiinflammatory activity in RBL2H3 cells assessed as inhibition of degranulation Antiinflammatory activity in RBL2H3 cells assessed as inhibition of degranulation	[PMID: 24316124]
SiHa	IC₅₀	53.76 μM Compound: 2	Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs	[PMID: 31539776]
SiHa	IC₅₀	53.8 μM Compound: 2	Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31539776]
SK-MEL-28	IC₅₀	75 μM Compound: 20	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
THP-1	CC₅₀	250 μM Compound: Isoliquiritigenin	Cytotoxicity against human THP-1 cells Cytotoxicity against human THP-1 cells	[PMID: 31924495]
THP-1	IC₅₀	10.1 μM Compound: Isoliquiritigenin	Inhibition of NLRP3 in human THP1 cells assessed as inhibition of MSU-induced IL-1beta production Inhibition of NLRP3 in human THP1 cells assessed as inhibition of MSU-induced IL-1beta production	[PMID: 31924495]
U-373MG ATCC	IC₅₀	68 μM Compound: 20	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
Vero	IC₅₀	65.6 μM Compound: 9	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 16441066]
Vero	CC₅₀	463.65 μg/mL Compound: 30	Cytotoxicity against african green monkey Vero cells assessed as cell death after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as cell death after 72 hrs by MTT assay	[PMID: 22169259]
Vero	IC₅₀	31.25 μg/mL Compound: 30	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 22169259]

In Vitro

Isoliquiritigenin may prevent diabetic complications through inhibiting rat lens aldose reductase with IC₅₀=320 nM and sorbitol accumulation in human red blood cells with IC₅₀=2.0 μM^[1]. Isoliquiritigenin (100 μM) markedly inhibits the hypoxia-induced prolonged TPS and TR90 of cardiomyocytes. Isoliquiritigenin significantly triggers AMPK Thr172 phosphorylation as compared with vehicle group. Isoliquiritigenin treatment also induces extracellular signal-regulated kinase (ERK) signaling pathway in the cardiomyocytes. Isoliquiritigenin treatment significantly decreases the intracellular ROS levels of isolated cardiomyocytes during hypoxia/reoxygenation^[3]. Isoliquiritigenin not only downregulates IL-6 expression but also significantly decreases levels of phosphorylated ERK and STAT3 and can inhibit phosphorylation levels of ERK and STAT3 induced by recombinant human IL-6, which are critical signaling proteins in IL-6 signaling regulation networks^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Isoliquiritigenin shows concentration-dependent inhibition of the tonic contraction of mouse jejunum induced by various types of stimulants such as CCh (1 mM), KCl (60 mM) and BaCl₂ (0.3 mM) with IC₅₀ values of 4.96±1.97 mM, 4.03±1.34 mM and 3.70±0.58 mM, respectively^[2]. Isoliquiritigenin exhibits significant anti-tumor activity in MM xenograft models and synergistically enhances the anti-myeloma activity of adriamycin^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 961-29-5
Appearance Solid
Molecular Weight 256.25
Formula C₁₅H₁₂O₄
Color Light yellow to yellow
SMILES

O=C(C1=CC=C(O)C=C1O)/C=C/C2=CC=C(O)C=C2
Synonyms

GU17; ISL; Isoliquiritigen; SJ000286237
Structure Classification
- Flavonoids
- Chalcones
- Phenols
- Polyphenols
Initial Source
- Microorganisms
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (32)

All IHCWB

Sort by:

Journal Impact Factor

Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Phytomedicine

Amoebicidal action of isoliquiritigenin and glabridin from Glycyrrhiza species: Mechanisms and effects against Acanthamoeba castellanii. [Abstract]

2025 Sep:145:157081. PMID: 40701128
Phytomedicine

Isoliquiritigenin alleviates abnormal sarcomere contraction and inflammation in myofascial trigger points via the IL-17RA/Act1/p38 pathway in rats. [Abstract]

2025 Jun 25:145:156993. PMID: 40592078
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

Isoliquiritigenin mitigates oxidative damage after subarachnoid hemorrhage in vivo and in vitro by regulating Nrf2-dependent Signaling Pathway via Targeting of SIRT1. [Abstract]

2022 Oct:105:154262. PMID: 35896045
Free Radic Biol Med

Isoliquiritigenin attenuates cisplatin-induced hearing loss and ototoxicity by activating the Keap1-Nrf2-ARE pathway. [Abstract]

2025 Oct 3:241:599-616. PMID: 41046947
Biomed Pharmacother

Isoliquiritigenin alleviates SLC7A11-mediated efferocytosis inhibition to promote wounds healing in diabetes. [Abstract]

2024 Oct 18:180:117578. PMID: 39427549
Biomed Pharmacother

Isoliquiritigenin prevents Doxorubicin-induced hepatic damage in rats by upregulating and activating SIRT1. [Abstract]

2022 Feb:146:112594. PMID: 34968927
Antioxidants

Integration of Transcriptomic Analysis, Network Pharmacology, and Experimental Validation Demonstrates Enhanced Muscle-Protective Effects of Ethanol Extract of Jakyak-Gamcho-Tang. [Abstract]

2025 Jun 27;14(7):795. PMID: 40722900
Phytother Res

Activation of PGC-1α via isoliquiritigenin-induced downregulation of miR-138-5p alleviates nonalcoholic fatty liver disease. [Abstract]

2022 Feb;36(2):899-913. PMID: 35041255
Ind Crops Prod

2025 Dec 11;239:122458.
Cancer Cell Int

Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. [Abstract]

2021 Jun 5;21(1):291. PMID: 34090418
J Drug Deliv Sci Technol

2026 May 26;123:108520.
Front Pharmacol

Isoliquiritigenin ameliorates abnormal oligodendrocyte development and behavior disorders induced by white matter injury. [Abstract]

2024 Sep 11:15:1473019. PMID: 39323643
Int Immunopharmacol

Isoliquiritigenin alleviates neuropathic pain by reducing microglia inflammation through inhibition of the ERK signaling pathway and decreasing CEBPB transcription expression. [Abstract]

2024 Nov 2;143(Pt 3):113536. PMID: 39488922
Front Cell Dev Biol

Licarin-B Exhibits Activity Against the Toxoplasma gondii RH Strain by Damaging Mitochondria and Activating Autophagy. [Abstract]

2021 Jun 11:9:684393. PMID: 34179016
J Funct Foods

May 2022, 105058.
Heliyon

Embelin attenuates lipopolysaccharide-induced acute kidney injury through the inhibition of M1 macrophage activation and NF-κB signaling in mice. [Abstract]

2023 Feb 26;9(3):e14006. PMID: 36938407
J King Saud Univ Sci

August 2022, 102165.
Biology (Basel)

Isoliquiritigenin Prevents the Development of Nephropathy by an HFD in Rats Through the Induction of Antioxidant Production and Inhibition of the MD-2/TLR4/NF-κB Pathway. [Abstract]

2024 Nov 28;13(12):984. PMID: 39765652
Genomics

Transcriptomics and metabolomics reveal the induction of flavonoid biosynthesis pathway in the interaction of Stylosanthes-Colletotrichum gloeosporioides. [Abstract]

2021 Jul;113(4):2702-2716. PMID: 34111523
Onco Targets Ther

Effects of isoliquiritigenin on ovarian cancer cells. [Abstract]

2018 Mar 22:11:1633-1642. PMID: 29606882

Isoliquiritigenin purchased from MedChemExpress. Usage Cited in: Onco Targets Ther. 2018 Mar 22:11:1633-1642. [Abstract]

Isoliquiritigenin (ILQ) treatment affects the expression level of apoptosis-related proteins.
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
J Mol Histol

Isoliquiritigenin attenuates pathological cardiac hypertrophy via regulating AMPKα in vivo and in vitro. [Abstract]

2022 Aug;53(4):679-689. PMID: 35834120
Oncol Lett

Isoliquiritigenin inhibits cell proliferation and migration through the PI3K/AKT signaling pathway in A549 lung cancer cells. [Abstract]

2018 Nov;16(5):6133-6139. PMID: 30344755

Isoliquiritigenin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Nov;16(5):6133-6139. [Abstract]

Western blot analysis of the expression of E cadherin, N cadherin and vimentin in A549 cells following treatment with Isoliquiritigenin (ISL) for 48 h.
Chemotherapy

Isoliquiritigenin Suppresses Osteosarcoma U2OS Cell Proliferation and Invasion by Regulating the PI3K/Akt Signalling Pathway. [Abstract]

2018 Jun 22;63(3):155-161. PMID: 29936511

Isoliquiritigenin purchased from MedChemExpress. Usage Cited in: Chemotherapy. 2018 Jun 22;63(3):155-161. [Abstract]

Western blot analysis of the effect on Bcl2, Bax, and active Caspase-3 protein expression in Isoliquiritigenin (ISL) treated U2OS cells.
Open Life Sci

2017; 12: 300–307

Isoliquiritigenin purchased from MedChemExpress. Usage Cited in: Open Life Sci. 2017; 12: 300–307

Western blot assays detect apoptosis-related protein expression of Bax, Bcl-2, active caspase-3.
Scand J Immunol

Isoliquiritigenin limits inflammasome activation of macrophage via docking into Syk to alleviate murine non-alcoholic fatty liver disease. [Abstract]

2024 Apr 26:e13371. PMID: 38671579
Am J Transl Res

Isoliquiritigenin attenuates LPS-induced AKI by suppression of inflammation involving NF-κB pathway. [Abstract]

2018 Dec 15;10(12):4141-4151. PMID: 30662657

Isoliquiritigenin purchased from MedChemExpress. Usage Cited in: Am J Transl Res. 2018 Dec 15;10(12):4141-4151. [Abstract]

The expression of CD68, CD206, iNOS, MPO is determined by immunohistochemistry in four animal groups. LPS increases the expression of CD68, iNOS and MPO but decreases the expression of CD206 in murine kidney, while ISL reduces the expression of CD68, iNOS and MPO then increases the expression of CD206 in mice kidney after LPS injection.

Isoliquiritigenin purchased from MedChemExpress. Usage Cited in: Am J Transl Res. 2018 Dec 15;10(12):4141-4151. [Abstract]

ISL inhibits phosphorylation of IκB-α following LPS stimulation. The expressions of IκB-α and p-IκB are measured by western blot. The samples are harvested from cells and mice. The results show that ISL could effectively decrease protein levels of p-IκB in HK₂ of the LPS-induced mice but increase IκB-α.
SSRN

2025 Jul 10.
bioRxiv

2025 Feb 19.

Solvent & Solubility

In Vitro:

Ethanol : 100 mg/mL (390.24 mM; Need ultrasonic)

DMSO : ≥ 100 mg/mL (390.24 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9024 mL

19.5122 mL

39.0244 mL

5 mM

0.7805 mL

3.9024 mL

7.8049 mL

10 mM

0.3902 mL

1.9512 mL

3.9024 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline